New partnership between CCRM and MIP on Biomanufacturing Campus
CCRM and MIP have formalized their intent to co-develop a business case around the construction and operation of Canada’s largest and most advanced Contract Development and Manufacturing Organization (CDMO) that will focus on regenerative medicine-based technologies and cell and gene therapies. They have both signed a Letter of Intent that will initially produce cells and viral vectors for clinical trials and commercial-scale manufacturing.
“Our partnership with MIP is about more than building a facility, this is about building domestic manufacturing capacity within the region for the next generation of medical advances. Our expectation is that the biomanufacturing campus within MIP, and the CDMO, will result in jobs, economic stimulus for the region and, most importantly, life-saving products for patients.” Dr. Michael May, President and CEO, CCRM